Desay SV Unveils Cutting-Edge Automotive Technologies at IZB 2024

WEIMAR, Germany, Oct. 30, 2024 /PRNewswire/ -- The International Suppliers Fair (IZB) took place in Wolfsburg, Germany, from October 22nd to 24th, under the theme "Empowering Partnerships." This year, 830 exhibitors from around the globe came together to present the latest innovations in technology and products. Desay SV (002920.SZ), a leading mobility technology company, showcased over 50 advanced products from three business lines: Smart Cabin, Smart Drive, and Smart Service. This highlights its strategic vision of becoming the preferred partner in mobility transformation.

Intelligent Connected Vehicles Products for Global Customers

Desay SV showcased its range of mature products alongside cutting-edge innovations at the exhibition. Notable displays included various cabin products, such as the high-performance intelligent cabin G9SH, heads-up display (HUD), and intelligent surface (control panels). Additionally, Desay SV also featured various cameras, including OMS (Occupant Monitoring System), front-view, side-view, and other intelligent driving sensor solutions.

Among the various offerings, Desay SV's intelligent driving solutions stood out and captured significant attention. The highlight was the latest intelligent driving domain controller, the IPU14. Powered by the NVIDIA Thor chip, the IPU14 supports L3 conditional autonomous driving and L4 autonomous driving in specific scenarios. With its exceptional performance, safe and redundant design, and the ability to personalise driving efficiency and comfort through algorithmic enhancements, the IPU14 has already attracted pre-orders from several OEMs.

Desay SV Enhances Localised Services in the European Market

Yang Yong, Executive Vice President of Desay SV and General Manager of Desay SV Europe, shared insights in an interview during the IZB, highlighting that the true indicator of an enterprise's internationalisation lies in its ongoing success with localisation efforts. The European market plays a crucial role in Desay SV's plans for future growth and development. In the future, we plan to increase physical investment, optimise resource allocation across supply chains, manufacturing, management, and R&D, and fully guarantee supply chain security to provide local customers with more comprehensive and efficient services along the whole order cycle from R&D to manufacturing. While enhancing the local customer service capabilities, we also seek to strengthen local industrial partnerships and actively uphold corporate social responsibility.

Gao Dapeng, Chairman and President of Desay SV, who was invited to participate in the IZB Livestage "Electrification and Connectedness" seminar, said: "Through deep cooperation with global partners, Desay SV remains committed to a customer-orientated approach, aligning our services with customers' developing strategies. Industrial transformation doesn't happen overnight; each region has its own development pace and unique needs. Desay SV is eager to collaborate with customers to provide tailored solutions based on local demands, helping them lead the way in the automotive industry's transformation."

Recently, Desay SV has accelerated its European market strategy by establishing a new tech park in Weimar, Germany, opening the first office in Paris, France, and initiating an intelligent factory project in Spain. With these advancements, Desay SV has significantly strengthened local production capabilities, enabling it to better serve the vast European automotive market with shorter delivery times, quicker responses, and solutions that better match local expectations.

About Desay SV

Desay SV is a leading mobility technology company with R&D and service branches in Germany, Japan, Singapore, Spain, USA, etc. The company focuses on efficiently integrating smart cabin, smart drive, and smart service. Relying on 38 years of accumulation, Desay SV has excelled in R&D, design, quality management, and intelligent manufacturing. Desay SV's continuous innovation and comprehensive capabilities earn the long-term trust of global customers, including Chery, Geely, SAIC, Toyota, Volkswagen, Volvo, etc., and have helped it rank 74th in the Automotive News 2024 top 100 global auto parts suppliers. For more information, please visit Desay SV online at www.desaysv.com or follow us on: https://www.linkedin.com/company/13690363

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Desay SV Unveils Cutting-Edge Automotive Technologies at IZB 2024

Desay SV Unveils Cutting-Edge Automotive Technologies at IZB 2024

NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24^th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16^th World Stroke Conference (WSC). According to the latest data, the administration of edaravone dexborneol (Sanbexin®) in patients with acute ischemic stroke (AIS) before receiving endovascular thrombectomy significantly improved neuro-function recovery and reduced disability from stroke.

Presented as a WCS late-breaking oral presentation by Professor Yongjun Wang from Beijing Tiantan Hospital, the study entitled "Treatment of Acute ischemic Stroke with Edaravone dexborneal 2" ("TASTE-2") has caught wide spread attention among neurology academic circle in the world.

Stroke is the leading cause of death and disability in adults in China, while AIS accounts for about 70% of all strokes. About 40% of AIS patients fall into the category of large vessel occlusion (LVO), a subtype of AIS with higher disability and mortality.

After stroke, reperfusion treatments (e.g., thrombolysis and thrombectomy) are used to restores blood supply to the brain as soon as possible. The endovascular thrombectomy (EVT), an important advance in reperfusion therapy in recent years, can achieve recanalization in about 70% to 90% of patients with the LVO stroke, but only half of these patients achieve favorable brain function recovery A significant proportion of the patients who received EVT remain disabled to varying degrees after 90 days of treatment.

TASTE-2 study is a multicenter, double-blind, randomized, placebo-controlled clinical study. From March 2022 to May 2023, a total of 1362 AIS patients with a large-vessel occlusion (LVO) in the anterior circulation were enrolled. Patients were randomly allocated (1:1) to receive edaravone dexborneol (edaravone, 30 mg; (+)-dexborneol, 7.5 mg) or placebo prior to EVT and continued twice a day over a consecutive period of 10-14 days.  As a primary efficacy outcome, 379 (55.0%) patients in the edaravone dexborneol group and 333 (49.6%) in the placebo group achieved a mRS 0-2 at day-90 (odds ratio [OR] 1.24, 95% CI 1.00-1.54; risk ratio [RR] 1.11, 95% CI 1.00-1.23). All safety outcomes were similar between both groups. This suggests that Edaravone dexborneol could improve the favorable functional outcome at 90 days in AIS patients within 24-hour of symptom onset who underwent EVT.

Sanbexin® (Edaravone dexborneol Concentrated Solution for Injection) is a multi-targeted brain cell protection agent developed by Simcere Pharmaceutical Co., Ltd, and is the only approved innovative drug in the field of stroke treatment worldwide since 2015. Composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, the drug can significantly reduce brain cell injury or impairment caused by AIS.

According to the recommendations of the Stroke Academic Roundtable Meeting (STAIR), brain cytoprotectants can reduce ischemic brain injury, especially when combined with thrombectomy. The scientific community has also been working on brain cytoprotective agents for stroke treatment for decades. However, due to the complexity of stroke pathophysiology, single-target drugs have been found to have limited efficacy and difficult to be developed clinically.

On the other hand, the clinical study of multi-target brain cytoprotectants continue to progress. Previously, the TASTE study led by Professor Yongjun Wang's team in Beijing Tiantan Hospital and the TASTE-SL study led by Professor Dongsheng Fan in Peking University Third Hospital confirmed the efficacy of edaravone dexborneol injection and sublingual tablets in AIS patients who do not receive reperfusion treatment. The latest results of the TASTE-2 study provide key clinical medical evidence for Sanbexn® as a multi-target brain cell protection strategy combined with reperfusion in the treatment of acute ischemic stroke. Sanbexin® is expected to be used as a concomitant drug for endovascular treatment such as thrombectomy, particularly before reperfusion, to further improve the effect of stroke treatment and reduce stroke disability.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

World Stroke Congress | TASTE-2 significantly reduces stroke disability